US 8,435,948
Application 11/664,030 · Granted May 7, 2013
Methods for inhibiting osteoclastic bone resorption and bone loss comprising administration of an anti-fsh or anti-fshr antibody
Estimated expiration
April 16, 2028
1y 147d remaining
Earliest effective filing
Sep 27, 2005
+ 20 years
Sep 27, 2025
PTA +932d
Apr 16, 2028
No TD
—
Final
Apr 16, 2028
- Earliest effective filing
- Sep 27, 2005
- + 20 years
- Sep 27, 2025
- PTA +932d
- Apr 16, 2028
- No TD
- —
- Final
- Apr 16, 2028
This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.
Calculation details
Base term
- Filing date
- November 30, 2007
- Earliest effective filing
- September 27, 2005
- Issue date
- May 7, 2013
- PTA
- +932 days
- Base expiry (before PTA)
- September 27, 2025
September 27, 2005 + 20 years = September 27, 2025 + 932 PTA days = April 16, 2028
- National stage entry of application PCTUS2005035019, filed Sep 27, 2005
- PRO60/614,597 — Provisional — not used for base term
- PRO60/620,086 — Provisional — not used for base term
- PRO60/614,597 — Provisional — not used for base term
- PRO60/620,086 — Provisional — not used for base term
Terminal disclaimers
Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated
You have the date. Your AI can have the file.
Application 11/664,030 · US 8,435,948
PatentReply compiles the prosecution history behind US 8,435,948: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.
One new published application a month is free. The first compile takes a few minutes.
Strategy and filing changes require your approval.
Permanent link
www.patentreply.ai/tools/patent-expiration/US8435948Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.